Please Wait
Applying Filters...
menu
    • menu
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD

    Stock Recap
    #PipelineProspector

    Menu

    Imipenem Anhydrous

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,493Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    28/10/2024 Sandoz B2B
    Switzerland
    		 SANDOZ PRIVATE LIMITED Navi Mumbai IN R0-CEP 2010-170 - Rev 00 Imipenem monohydrate, Chemical synthesis, Sterile 2012-06-12 Withdrawn by Holder Chemical 2013-04-05 1226
    28/10/2024 Sun Pharmaceutical Industries Limited
    India
    		 SUN PHARMACEUTICAL INDUSTRIES LIMITED Mumbai IN CEP 2008-325 - Rev 03 Imipenem monohydrate, Sterile 2024-03-20 Valid Chemical 1226